Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423707 | 0.93 | CYP2C9 (0.75) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL29461451 | 0.93 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2294370 | 0.93 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL12422593 | 0.92 | CYP2C9 (0.88) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2299712 | 0.92 | CYP2C9 (0.84) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL12422527 | 0.91 | CYP2C9 (0.86) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2295518 | 0.91 | CYP2C9 (0.89) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL12422993 | 0.91 | CYP2C9 (0.85) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2295949 | 0.91 | CYP2C9 (0.85) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2300294 | 0.91 | CYP2C9 (0.76) | CYP2C9CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | claimed |
| EP-3199531-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9682999-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-9682999-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-8927593-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8927593-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2013028371-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | GLAXO GROUP LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | CYP2C9 43/4885CYP3A4 25/4885CYP2C19 34/4885 |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | CYP2C9 43/4885CYP3A4 25/4885CYP2C19 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.